9 active not recruiting. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Active not recruiting 9 |
| Phase 2 | 3 | Active not recruiting 3 |
Follow Bendamustine: new trials by email Literature Review of Bendamustine trials Research Report on Bendamustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients Atezolizumab, BEGEV - Relapsed or Refractory Hodgkin's Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 122 | 2023-02-27 | 2026-09-11 |
| A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Bendamustine, Rituximab, Tazemetostat - Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Vaishalee Kenkre | 42 | 2023-01-26 | 2026-02-17 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Nivolumab, Autologous CD30.CAR-T, Fludarabine - Classical Hodgkin Lymphoma, Hodgkin Disease Refractory | Phase 1 | Active not recruiting | Tessa Therapeutics | 15 | 2022-07-25 | 2023-04-03 |
| FT819 in Subjects With B-cell Malignancies FT819, Cyclophosphamide, Fludarabine - Lymphoma, B-Cell, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | Fate Therapeutics | 54 | 2021-07-12 | 2026-03-19 |
| Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma iC9-CAR19 T cells, Bendamustine, Fludarabine - Lymphoma, Lymphoma, B-Cell | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 12 | 2019-03-12 | 2026-07-31 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 43 | 2018-10-29 | 2026-06-12 |
| A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients rituximab, bendamustine, melphalan - Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 28 | 2017-11-20 | 2025-12-04 |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Active not recruiting | Kami Maddocks, MD | 48 | 2014-03-26 | 2026-07-22 |
Lymphoma (4) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Cytokine Release Syndrome (1) · Hodgkin Disease (1) · Immunoglobulin Light-chain Amyloidosis (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
UNC Lineberger Comprehensive Cancer Center (2) · Columbia University (1) · Fate Therapeutics (1) · Fondazione Italiana Linfomi - ETS (1) · Kami Maddocks, MD (1) · Memorial Sloan Kettering Cancer Center (1) · Tessa Therapeutics (1) · Vaishalee Kenkre (1)
United States (8) · Italy (1)
Natalie Grover, MD (2) · Armando Santoro, MD (1) · Helen Heslop, MD (1) · Kami Maddocks, MD (1) · Parastoo Dahi, MD (1) · Rajshekhar Chakraborty, MD (1) · Sairah Ahmed, MD (1) · Vaishalee Kenkre, MD (1)
K12CA120780 (1), R01CA247497 (1)